Xin Wei Wang
Laboratory of Human Carcinogenesis
The Center for Cancer Research
United States of America
Biography
Dr. Wang grew up in Shanghai, China where he received a Bachelor's degree from Shanghai First Medical College in 1982 and a Master's degree from the Chinese Academia of Science in 1984. He moved to the United States in the mid-80's and attended New York University School of Medicine for his Ph.D. studies. He received postdoctoral training at Roche Institute of Molecular Biology and subsequently at NCI. He was recruited to NCI as a tenure track investigator in 1998 and was promoted as a tenured Senior Investigator in 2005. The Wang lab utilizes state-of-the-art technologies to study primary liver cancer. Dr. Wang has led several major international research initiatives on liver cancer genomics studies through collaborations with multiple universities and cancer centers. He is recipients of the NIH Merit Award, the NCI Director Award and the NIH Asian & Pacific Islander American Organization Award for his outstanding accomplishments in biomedical research. He is also a recipient of the NCI Mentor of Merit Award for excellence in mentoring and guiding the careers of trainees in cancer research. He is a recipient of an Honorary Professorship from Fudan University and a SCBA Outstanding Leadership and Service Award. He has coauthored over 150 peer-reviewed manuscripts and book chapters. He is frequently invited to give lectures at international conferences and academic institutions. He serves on many scientific committees and provides numerous editorial services and grant reviews.
Research Interest
Cancer Biology, Cell Biology, Genetics and Genomics, Molecular Biology and Biochemistry, Systems Biology
Publications
-
Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 9: 416-23.
-
Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 10: 99-111.
-
Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 361: 1437-47.
-
Roessler S, Long EL, Budhu A, Chen Y, Zhao X, et al. (2012) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 142: 957-66.
-
Parpart S, Roessler S, Dong F, Rao V, Takai A, et al. (2014) Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology. 60: 872-83.
